Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST): An Open Label Dose Escalation Phase 1 Trial Followed by a Randomised, Double-blind, Allocation Concealed, Placebo-controlled Trial.

NCT03042143 is registered in ClinicalTrials.gov with Belfast Health and Social Care Trust as lead sponsor.

NCT NCT03042143
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03042143 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST): An Open Label Dose Escalation Phase 1 Trial Followed by a Randomised, Double-blind, Allocation Concealed, Placebo-controlled Trial.
Lead sponsor
Belfast Health and Social Care Trust
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
January 7, 2019
Completion date
October 31, 2026
Enrollment
129 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute respiratory distress syndrome